Primer Ventures

Name

Primer Ventures

Legal name

Primer Ventures

Website

https://primerventures.com

Company type

Private

Operating status

Operating

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Portfolio Returns and Exit Proceeds: Primer Ventures generates returns through equity investments in early-stage life science companies. Returns are realized through portfolio company exits via acquisitions or IPOs, such as the acquisition of Curio Bioscience by Takara.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Primer Ventures is an early-stage venture capital firm that invests in breakthrough innovations in life science tools and therapeutics. The firm provides capital, strategic partnership, and operational support to visionary entrepreneurs building companies across synthetic biology, genomics and proteomics, single cell and spatial biology, molecular diagnostics, cell and gene therapies, regenerative medicines, and AI-enabled drug discovery. Returns are realized through portfolio company exits such as acquisitions and IPOs.

Product overview

Primer Ventures operates as an early-stage venture capital firm rather than a product company. Its core offering is the Primer Ventures Fund, which invests in breakthrough life science innovations across two broad domains: Tools and Genomics (including synthetic biology, genomics and proteomics, single cell and spatial biology, next-gen analytical equipment, molecular diagnostics, and manufacturing technologies) and Therapeutics (covering new therapeutic modalities, genetic medicine, new delivery methods, cell and gene therapies, regenerative medicines, and omics and AI-enabled drug discovery). The portfolio comprises portfolio company holdings including Curio Bioscience (single-cell spatial profiling, acquired by Takara), Countable Labs (next-generation digital counting platform), BH Therapeutics (targeted therapies for drug resistance), and AllInBio (immunology therapeutics for autoimmune diseases), representing early-stage companies across tools, genomics, and therapeutic development.

Differentiator

Problem solved

Functional benefit

Products and services

• Primer Ventures Fund

Quantifiable outcome

• Portfolio company Curio Bioscience successfully acquired by Takara, demonstrating successful exit and value creation

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Direct peers

• Atlas Venture: Early-stage life sciences VC building biotech companies from inception, with strong focus on therapeutics and platform technologies. Closely mirrors Primer's strategy of seeding breakthrough therapeutics and tools, making it a strong direct peer despite its larger AUM.
• Abingworth: Life sciences-focused investment firm with strategies across venture, growth, and public equities in biotech. Closely comparable to Primer's thematic concentration on life sciences tools and therapeutics.
• Versant Ventures: Healthcare-focused VC investing across biotech, medical devices, and healthcare services with significant early-stage activity. Comparable to Primer in its early-stage life sciences focus and thematic portfolio construction, though with broader stage flexibility.
• MPM Capital: Specialist life sciences VC investing in early- and mid-stage biotech and oncology companies. Comparable to Primer's therapeutic focus and early-stage orientation, with a comparable thematic concentration.
• Frazier Healthcare Partners: Healthcare-dedicated VC with both life sciences and provider services franchises, with significant early-stage biotech activity. Comparable to Primer's vertical specialization in life sciences.
• Omega Funds: Healthcare-dedicated investment firm focused on both private and public life sciences companies, with strong early-stage therapeutic emphasis. Comparable in vertical focus to Primer.
• 5AM Ventures: Early-stage venture capital firm focused on building next-generation life science companies, with emphasis on biotech tools and therapeutics. Closely aligned with Primer's fund strategy and target sectors.

Broad incumbents

• ARCH Venture Partners: One of the largest and most established early-stage life sciences VCs, investing across biotech, tools, genomics, and frontier biology. Directly comparable to Primer as an early-stage life sciences specialist, but with materially larger AUM and broader partnership. Primer's visible co-investment relationship with ARCH makes it the most relevant comparison point.
• Flagship Pioneering: Cambridge-based VC that originates and builds companies in life sciences and biotechnology, including AI-enabled drug discovery (e.g., partnerships with Pfizer). Comparable to Primer in its early-stage orientation and focus on breakthrough life science platforms, but operates at significantly larger scale.
• New Enterprise Associates (NEA): Large multi-stage VC with a dedicated life sciences practice investing across biotech, tools, and therapeutics at multiple stages. Comparable to Primer in sector but with vastly broader sector and stage breadth.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Primer Ventures